keyword
MENU ▼
Read by QxMD icon Read
search

Non Clear Cell RCC

keyword
https://www.readbyqxmd.com/read/27920423/de-novo-renal-neoplasia-after-kidney-transplantation-according-to-new-2016-who-classification-of-renal-tumors
#1
Albino Eccher, Luigino Boschiero, Brett Delahunt, Luca Cima, Francesca Fior, Francesco Nacchia, Momo Rostand, Amedeo Carraro, Umberto Tedeschi, Gianluigi Zaza, Marilena Casartelli Liviero, Laura Zampicinini, Marco Chilosi, Giuseppe Feltrin, Claudio Rago, Antonietta D'Errico, Claudio Ghimenton, Guido Martignoni, Matteo Brunelli
BACKGROUND De novo renal neoplasia developing after kidney transplantation at Verona Kidney Transplant Center were reviewed according to new 2016 WHO Renal Tumor Classification. MATERIAL AND METHODS Primary renal tumors developed in native or transplanted kidneys de novo following renal transplantation were retrieved and histologically reviewed by three expert uropathologists. Immunoexpression of the diagnostic antigens CD13, CD10, CK7, CK34bE12, AMACR, CAIX, AE1/AE3, CK14, GATA-3, HMB-45, cathepsin-k, S100A1, and parvalbumin was assessed...
December 6, 2016: Annals of Transplantation: Quarterly of the Polish Transplantation Society
https://www.readbyqxmd.com/read/27919135/-bladder-metastasis-of-renal-cell-carcinoma-7-years-after-ex-vivo-partial-nephrectomy-and-auto-transplantation-a-case-report
#2
Takuya Owari, Tomoki Yamamoto, Shinichiro Mizobuchi, Yositaka Itami, Tomonori Nakahama, Yosihiro Matsumoto, Hitoshi Momose
Metastasis of renal cell carcinoma (RCC) to urinary bladder is extremely rare. We report a case of metastasis arising from RCC to the urinary bladder 7 years after treatment of bilateral RCC. A 74-year-old man was diagnosed with bilateral multiple renal tumors (T1aN0M1, PUL, OSS) with two lesions in the right kidney and a solitary lesion of the left kidney in 2008. He underwent laparoscopic radical nephrectomy for the right side in September 2008. The next month, ex vivo partial nephrectomy and auto-transplantation was performed for the left kidney because the tumor was located very close to the collecting system...
November 2016: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/27907929/critical-evaluation-of-the-potential-prognostic-value-of-the-pretreatment-derived-neutrophil-lymphocyte-ratio-under-consideration-of-c-reactive-protein-levels-in-clear-cell-renal-cell-carcinoma
#3
Orietta Dalpiaz, Theresa Luef, Maximilian Seles, Michael Stotz, Tatjana Stojakovic, Karl Pummer, Richard Zigeuner, Georg C Hutterer, Martin Pichler
BACKGROUND: We investigated the prognostic value of the pretreatment-derived neutrophil-lymphocyte ratio (dNLR) and original NLR in relation to the commonly used inflammation marker C-reactive protein (CRP) in a large cohort of patients with clear cell renal cell carcinoma (RCC). METHODS: Clinicopathological data from 587 consecutive non-metastatic clear cell RCC patients, operated between 2000 and 2010 at a single tertiary academic center, were evaluated retrospectively...
December 1, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/27904651/sunitinib-in-the-treatment-of-metastatic-renal-cell-carcinoma
#4
REVIEW
Thomas A Schmid, Martin E Gore
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib received approval in 2006 and became a standard treatment option in the first-line treatment of metastatic renal cell cancer (mRCC) after a phase III trial showed superiority compared with interferon alpha (IFN-α). Sunitinib has also shown activity in second-line treatment in several trials. Most of the combination trials with sunitinib with various agents have led to considerable toxicity without improving efficacy...
December 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27896403/histology-is-a-prognostic-indicator-after-pulmonary-metastasectomy-from-renal-cell-carcinoma
#5
Yoichi Ohtaki, Kimihiro Shimizu, Keiju Aokage, Masayuki Nakao, Junji Yoshida, Mitsuhiro Kamiyoshihara, Masayuki Sugano, Yusuke Takahashi, Seshiru Nakazawa, Toshiteru Nagashima, Kai Obayashi, Tomoyuki Hishida, Masahiro Tsuboi, Shohei Mori, Mingyon Mun, Sakae Okumura, Hitoshi Igai, Noriyuki Matsutani, Akira Mogi, Hiroyuki Kuwano
OBJECTIVES: There are only a few detailed reports concerning the prognosticators following surgical resection of pulmonary metastases (PMs) from renal cell carcinoma (RCC). We investigated the prognosis of patients with RCC PMs undergoing pulmonary metastasectomy and identified prognostic factors in a multi-institutional retrospective study. METHODS: We retrospectively evaluated 84 patients who underwent resection of PMs from RCC between 1993 and 2014. We assessed the clinicopathological characteristics, focusing on the histological findings of PMs...
November 28, 2016: World Journal of Surgery
https://www.readbyqxmd.com/read/27886176/a-feed-forward-loop-between-lncarsr-and-yap-activity-promotes-expansion-of-renal-tumour-initiating-cells
#6
Le Qu, Zhenjie Wu, Yaoming Li, Zhipeng Xu, Bing Liu, Feng Liu, Yi Bao, Dengshuang Wu, Jiayi Liu, Anbang Wang, Xiaoyuan Chu, Yinghao Sun, Cheng Chen, Zhengyu Zhang, Linhui Wang
Renal tumour-initiating cells (T-ICs) contribute to tumorigenesis, progression and drug resistance of renal cell carcinoma (RCC). However, the underlying mechanism for the propagation of renal T-ICs remains unclear. Here we show that long non-coding RNA lncARSR is upregulated in primary renal T-ICs and associated with a poor prognosis of clear cell RCCs (ccRCC). Knockdown of lncARSR attenuates the self-renewal, tumorigenicity and metastasis of renal T-ICs. Conversely, forced lncARSR expression enhances T-IC properties of RCC cells...
November 25, 2016: Nature Communications
https://www.readbyqxmd.com/read/27877211/the-three-gene-signature-in-urinary-extracellular-vesicles-from-patients-with-clear-cell-renal-cell-carcinoma
#7
Giuseppe De Palma, Fabio Sallustio, Claudia Curci, Vanessa Galleggiante, Monica Rutigliano, Grazia Serino, Pasquale Ditonno, Michele Battaglia, Francesco P Schena
Renal cell carcinoma (RCC) accounts for more than 2% of neoplasias in humans worldwide. Renal biopsy is the gold standard among the diagnostic procedures, but it is invasive and not suitable for all patients. Therefore, new reliable and non-invasive biomarkers for RCC are required. Secretion of extracellular vesicles (EVs), containing RNA molecules that can be transferred between cells, appears to be a common feature of neoplasia. Consistently, cancer-derived EVs are increased in blood and urine. Therefore, urinary samples may be a non-invasive approach for discovering new diagnostic biomarkers...
2016: Journal of Cancer
https://www.readbyqxmd.com/read/27834463/gene-expression-profile-of-renal-cell-carcinomas-after-neoadjuvant-treatment-with-sunitinib-new-pathways-revealed
#8
Carlos Dzik, Sabrina T Reis, Nayara I Viana, Glauber Brito, Isis Paloppi, Willian Nahas, Miguel Srougi, Katia R M Leite
BACKGROUND: In renal cell carcinoma (RCC) of the clear cell type, inactivity of the VHL gene induces overexpression of HIF1 α and its targets, the tyrosine kinase receptors, promoting RCC development and progression. The discovery of tyrosine kinase inhibitors (TKIs) changed the treatment of these tumors. Other molecular pathways involved in the TKI mechanisms of action have not been described in the literature. The aim of our study was to elucidate alternative mechanisms of action of sunitinib in tumor tissue after neoadjuvant treatment of RCC...
November 1, 2016: International Journal of Biological Markers
https://www.readbyqxmd.com/read/27833401/comparison-of-biexponential-and-monoexponential-model-of-diffusion-weighted-imaging-for-distinguishing-between-common-renal-cell-carcinoma-and-fat-poor-angiomyolipoma
#9
Yuqin Ding, Mengsu Zeng, Shengxiang Rao, Caizhong Chen, Caixia Fu, Jianjun Zhou
OBJECTIVE: To compare the diagnostic accuracy of intravoxel incoherent motion (IVIM)-derived parameters and apparent diffusion coefficient (ADC) in distinguishing between renal cell carcinoma (RCC) and fat poor angiomyolipoma (AML). MATERIALS AND METHODS: Eighty-three patients with pathologically confirmed renal tumors were included in the study. All patients underwent renal 1.5T MRI, including IVIM protocol with 8 b values (0-800 s/mm(2)). The ADC, diffusion coefficient (D), pseudodiffusion coefficient (D(*)), and perfusion fraction (f) were calculated...
November 2016: Korean Journal of Radiology: Official Journal of the Korean Radiological Society
https://www.readbyqxmd.com/read/27816876/differentiation-of-subtypes-of-renal-cell-carcinoma-dynamic-contrast-enhanced-magnetic-resonance-imaging-versus-diffusion-weighted-magnetic-resonance-imaging
#10
Akira Yamamoto, Tsutomu Tamada, Katsuyoshi Ito, Teruki Sone, Akihiko Kanki, Daigo Tanimoto, Yasufumi Noda
OBJECTIVE: The objective was to compare the performance of dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance (MR) imaging in the differentiation of subtypes of renal cell carcinoma (RCC). MATERIALS/METHODS: This study included 45 renal tumors of clear cell (n=36) and non-clear-cell (n=9) RCC. The contrast enhancement ratios (CERs) and the apparent diffusion coefficient (ADC) values on MR imaging were compared between the clear cell and non-clear-cell RCC groups...
October 7, 2016: Clinical Imaging
https://www.readbyqxmd.com/read/27802451/microrna-193b-3p-as-a-predictive-biomarker-of-chronic-kidney-disease-in-patients-undergoing-radical-nephrectomy-for-renal-cell-carcinoma
#11
Francesco Trevisani, Michele Ghidini, Alessandro Larcher, Andrea Lampis, Hazel Lote, Paolo Manunta, Maria Teresa Sciarrone Alibrandi, Laura Zagato, Lorena Citterio, Giacomo Dell'Antonio, Cristina Carenzi, Giovambattista Capasso, Massimo Rugge, Paolo Rigotti, Roberto Bertini, Luciano Cascione, Alberto Briganti, Andrea Salonia, Fabio Benigni, Chiara Braconi, Matteo Fassan, Jens Claus Hahne, Francesco Montorsi, Nicola Valeri
BACKGROUND: A significant proportion of patients undergoing radical nephrectomy (RN) for clear-cell renal cell carcinoma (RCC) develop chronic kidney disease (CKD) within a few years following surgery. Chronic kidney disease has important health, social and economic impact and no predictive biomarkers are currently available. MicroRNAs (miRs) are small non-coding RNAs implicated in several pathological processes. METHODS: Primary objective of our study was to define miRs whose deregulation is predictive of CKD in patients treated with RN...
November 22, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/27761799/neuropeptide-levels-as-well-as-neprilysin-activity-decrease-in-renal-cell-carcinoma
#12
Nuray Erin, Tümay İpekçi, Bahar Akkaya, İrem Hicran Özbudak, Mehmet Baykara
Calcitonin Gene-related Peptide (CGRP), Vasoactive Intestinal Peptide (VIP) and Substance P (SP) are sensory neuropeptides which may alter cancer growth through modulation of chronic inflammation. We recently reported that SP suppresses breast cancer growth and metastasis through neuroimmune modulation. These neuropeptides are hydrolyzed by Neprilysin (NEP) to bioactive fragments. Decreased activity of NEP was reported in clear cell and chromophobe type renal cell carcinoma (RCC). It is however not known how the levels of neuropeptides hydrolyzed with NEP changes in RCC...
October 19, 2016: Cancer Microenvironment: Official Journal of the International Cancer Microenvironment Society
https://www.readbyqxmd.com/read/27748279/diagnostic-utility-of-wilms-tumour-1-protein-wt-1-immunostaining-in-paediatric-renal-tumours
#13
Surbhi Goyal, Kiran Mishra, Urvee Sarkar, Satendra Sharma, Anita Kumari
BACKGROUND & OBJECTIVES: Renal tumours constitute about 7 per cent of all neoplasms in children. It is important to differentiate Wilms' tumour (commonest tumour) from non-Wilms' tumours. The aim of this study was to evaluate the immunoexpression and diagnostic role of Wilms' tumour-1 protein (WT1) in paediatric renal tumours. METHODS: A total of 53 cases of renal tumours in children (below 18 yr) who underwent total nephrectomy were included in this retrospective study...
May 2016: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/27746886/unusual-ultrasound-presentation-of-testicular-metastasis-from-renal-clear-cell-carcinoma
#14
Lucio Dell'Atti
Testicular metastases from renal clear cell carcinoma (RCC) are extremely uncommon. To the best of our knowledge, only 32 cases have been reported in the literature. We report a rare case of testicular metastasis from RCC. A 69-year-old patient presented with discomfort and pain in his left testis. He had undergone laparoscopic left radical nephrectomy at another institution. Scrotal ultrasonography revealed a non-palpable lesion at the upper pole of the left testis with hypoechoic aspect, highly suspicious for malignancy...
September 5, 2016: Rare Tumors
https://www.readbyqxmd.com/read/27743018/a-practical-imaging-classification-for-the-non-invasive-differentiation-of-renal-cell-carcinoma-into-its-main-subtypes
#15
Brindley David Cupido, Medica Sam, Sean David Winters, Bilal Ahmed, Michael Seidler, Guan Huang, Gavin Low
AIM: Renal cell carcinoma (RCC) is a heterogeneous disease which encompasses various subtypes that exhibit differing biologic behavior and imaging findings. Non-invasive subtype differentiation by imaging facilitates prognostication and treatment selection. The aim of the study was to evaluate the performance of a diagnostic imaging key based on tumor morphology, T2 signal intensity on MRI, and tumor vascularity for differentiating RCC into its subtypes. MATERIALS AND METHODS: Using a custom-designed diagnostic imaging key, three blinded fellowship-trained abdominal radiologists independently evaluated the cross-sectional imaging of 50 histologically proven RCCs and categorized these into subtypes in two sessions...
October 14, 2016: Abdominal Radiology
https://www.readbyqxmd.com/read/27738339/mir-99b-5p-expression-and-response-to-tyrosine-kinase-inhibitor-treatment-in-clear-cell-renal-cell-carcinoma-patients
#16
Magdalena Lukamowicz-Rajska, Christiane Mittmann, Michael Prummer, Qing Zhong, Jens Bedke, Jörg Hennenlotter, Arnulf Stenzl, Axel Mischo, Svenja Bihr, Manuela Schmidinger, Ursula Vogl, Iris Blume, Christoph Karlo, Peter Schraml, Holger Moch
A number of treatments targeting VEGF or mTOR pathways have been approved for metastatic clear cell Renal Cell Carcinoma (ccRCC), but the majority of patients show disease progression after first line therapy with a very low rate of complete or long-term responders. It has been shown that miRs may play a role in prediction of treatment response in various cancer types. The aim of our study was to identify a miR signature predictive for RCC patients' response to antiangiogenic tyrosine kinase inhibitor (TKI) treatment in the first line therapy...
October 12, 2016: Oncotarget
https://www.readbyqxmd.com/read/27733182/an-xp11-2-translocation-renal-cell-carcinoma-with-smarcb1-ini1-inactivation-in-adult-end-stage-renal-disease-a-case-report
#17
Lu Yu, Jun Li, Sanpeng Xu, Mariajose Navia Miranda, Guoping Wang, Yaqi Duan
BACKGROUND: Xp11.2 translocation/transcription factor E3 (TFE3) rearrangement renal cell carcinoma (RCC) is a rare subtype of RCC with limited clinical and pathological data. CASE PRESENTATION: Here we present an unusual high-grade Xp11.2 translocation RCC with a rhabdoid feature and SMARCB1 (INI1) inactivation in a 40-year-old man with end-stage kidney disease. The histological examination of the dissected left renal tumor showed an organoid architecture of the eosinophilic or clear neoplastic cells with necrosis and high mitotic activity...
October 12, 2016: Diagnostic Pathology
https://www.readbyqxmd.com/read/27720164/survival-of-patients-with-advanced-or-metastatic-renal-cell-carcinoma-in-routine-practice-differs-from-that-in-clinical-trials-analyses-from-the-german-clinical-rcc-registry
#18
Norbert Marschner, Michael Staehler, Lothar Müller, Arnd Nusch, Johanna Harde, Michaela Koska, Martina Jänicke, Peter J Goebell
INTRODUCTION: Because "real-life" patients often do not meet the strict eligibility criteria of clinical trials, we assessed the trial eligibility of patients with advanced or metastatic renal cell carcinoma (mRCC) in routine practice and compared the survival of "trial-ineligible" and potentially "trial-eligible" patients. PATIENTS AND METHODS: The present prospective, multicenter German cohort study is recruiting patients from 110 oncology/urology outpatient centers and hospitals at initiation of systemic first-line treatment...
September 8, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27713637/safety-and-efficacy-of-sunitinib-in-patients-from-latin-america-subanalysis-of-an-expanded-access-trial-in-metastatic-renal-cell-carcinoma
#19
Carlos H Barrios, Daniel Herchenhorn, Matías Chacón, Paula Cabrera-Galeana, Peter Sajben, Ke Zhang
BACKGROUND: Sunitinib is an approved treatment for metastatic renal cell carcinoma (mRCC). The safety profile and efficacy of sunitinib were confirmed in a global expanded access trial (ClinicalTrials.gov identifier: NCT00130897). This report presents a subanalysis of the final trial data from patients in Latin America. METHODS: Treatment-naïve or previously treated mRCC patients aged ≥18 years received oral sunitinib at a starting dose of 50 mg/day on a 4-weeks-on/2-weeks-off schedule...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27705920/integrative-analysis-of-protein-coding-and-non-coding-rnas-identifies-clinically-relevant-subtypes-of-clear-cell-renal-cell-carcinoma
#20
Zongcheng Li, Yaowen Chen, Shuofeng Hu, Jian Zhang, Jiaqi Wu, Wu Ren, Ningsheng Shao, Xiaomin Ying
Protein-coding genes and non-coding RNAs cooperate mutually in cells. Integrative analysis of protein-coding and non-coding RNAs may facilitate characterizing tumor heterogeneity. We introduced integrated consensus clustering (ICC) method to integrate mRNA, miRNA and lncRNA expression profiles of 431 primary clear cell renal cell carcinomas (ccRCCs). We identified one RCC subgroup easily misdiagnosed as ccRCC in clinic and four robust ccRCC subtypes associated with distinct clinicopathologic and molecular features...
September 29, 2016: Oncotarget
keyword
keyword
104989
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"